Andrew C. Lam

No open positions remaining

Health Technology

Consumer Services

Profile

Andrew C.
Lam is the founder of Endurance Bio, Inc. Mr. Lam is Vice President-Product Development at Armetheon, Inc. Mr. Lam was Senior Director-Liquid OROS Technology Development at ALZA Corp., Executive Director-Formulation Development at Exelixis, Inc., and Executive Director-Product Development at Altheos, Inc. Mr. Lam completed undergraduate studies at the University of California, Davis.

Andrew C. Lam active positions

Companies	Position	Start
Armetheon, Inc. Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cardiovascular focused late-clinical stage specialty pharmaceutical company	Corporate Officer/Principal	-

All active positions of Andrew C. Lam

Former positions of Andrew C. Lam

Companies	Position	End
EXELIXIS, INC.	Corporate Officer/Principal	-
ALZA CORPORATION	Corporate Officer/Principal	-
Altheos, Inc. Altheos, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products	Corporate Officer/Principal	-

See the detail of Andrew C. Lam's experience

Training of Andrew C. Lam

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Andrew C. Lam's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
ALZA Corp. ALZA Corp. Pharmaceuticals: MajorHealth Technology Provides and develops pharmaceutical products	Health Technology
Exelixis, Inc. Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company	Health Technology
University of California, Davis University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Altheos, Inc. Altheos, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products	Health Technology
Armetheon, Inc. Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cardiovascular focused late-clinical stage specialty pharmaceutical company	Health Technology